Paul Calabresi Clinical Oncology K12 Program Scholars
Janai Carr-Ascher, M.D., Ph.D.
Development of a Phenotypically Diverse Sarcoma Pre-Clinical Disease Model to Identify Novel Therapeutic Approaches
May Cho, M.D.
Development of Oxaliplatin-DNA adduct formation as a biomarker in gastrointestinal malignancies
Amanda Kirane, M.D.
Assessment of immune phenotype and patterns of response to neoadjuvant oncolytic virus in high risk, resectable melanoma
Tzu-yin (Cindy) Lin, D.V.M., Ph.D.
Multi-functional bladder-targeting Nanoporphyrin medicated phototherapy to potentiate immunotherapy
Lorenzo Nardo, M.D., Ph.D.
Optimized PET/CT: Clinical applications in lung cancer
Mamta Parikh, M.D., M.S.
Pilot study evaluating safety of selinexor and its effect on XPO1 expression in bladder and renal cancers
Aaron Seth Rosenberg, MD, MS
Evaluating High Dose Melphalan Pharmacokinetics, Predictors of Variability, and its’ effect on Toxicity and Efficacy
Guobao Wang, Ph.D.
School of Medicine Dean's Scholar in Clinical Oncology
One-stop shop multiparametric PET imaging of cancer treatment response and organ chemotoxicity for targeted therapy
Gustavo Barisone, Ph.D.
Phase I/II trial of FWGP in patients with NHL receiving rituximab therapy
Jenna Burton, D.V.M., M.S., DACVIM
Contributions of B-cell lymphoma microenvironment in the development of drug resistance
Robert Canter, M.D,. M.A.S., FACS
Exploring novel treatment approaches in soft tissue sarcoma
Luis Carvajal-Carmona, B.Sc., Ph.D.
Colorectal cancer gene discovery in Hispanics through whole genome sequencing
Megan Daly, M.D.
Extending the benefit of immunotherapy for metastatic non-small cell lung cancer with ablative radiation
Elizabeth David, M.D., FACS
Understanding decision-making for surgery in advanced stage non-small cell lung cancer patients
Brian Jonas, M.D., Ph.D.
A daunorubicin and cytarabine microdosing feasibility study in adult acute myeloid leukemia
Edward Kim, M.D., Ph.D.
Aurora kinase inhibition in pancreatic cancer
Maija Kiuru, M.D., Ph.D.
Molecular subtyping of nevi and melanoma to improve diagnostic accuracy and identify drivers of melanomagenesis
Jonathan Riess, M.D.
Overcoming resistance to epidermal growth factor receptor tyrosine linase inhibitors (EGFR-TKIs) by linking patient derived lung cancer xenotransplants to clinical trials
Thomas Semrad, M.D., M.A.S.
Eliminating resistance to anti-vascular endothelial growth factor (VEGF) therapy through translational clinical trials and alternative angiogenic pathway